NorthWest Biotherapeutics Inc (NWBO)

[KRISGO]

I’m a little curious about whether there’s a chance Northwest will disclose the amount in the next 10-Q. Take a look at the below:

The docket update you’ve highlighted is the Order of Dismissal with Prejudice, which is the legal "final bell" for the Canaccord portion of the lawsuit.

To your question about the 10-Q filing (expected mid-May), the answer is a mix of "yes" and "maybe." Here is how Northwest Biotherapeutics (NWBO) will likely handle this disclosure based on SEC regulations and common legal strategy:

1. Must they disclose the amount? (The "10% Rule")

Under SEC Item 103 of Regulation S-K, a company must disclose "material" legal proceedings. If the settlement amount is significant enough to impact the company's financial health, they are technically required to report it.

The Threshold: Generally, if a settlement involves an amount exceeding 10% of the company's current assets, it is considered "material" and must be disclosed.

The Conflict: Often, settlement agreements have confidentiality clauses. If the deal with Canaccord is confidential, NWBO may only report that a "settlement was reached for an undisclosed amount" unless the SEC determines that the amount is so large that withholding it would be misleading to investors.

2. Where the money goes: The "Trust" vs. Operations

You mentioned the money going to a "trust." In high-stakes litigation, settlement funds are often placed in an Escrow Account or a Litigation Trust before being transferred to the company's general treasury.

10-Q Impact: Even if the money is in a trust, it must be reflected on the Balance Sheet as either "Cash," "Restricted Cash," or a "Legal Receivable."

The "Audit" Trail: Investors will be looking at the "Other Income" or "Cash Flow from Investing/Financing Activities" sections. Even if they don't name the exact dollar amount in the text, a sudden "spike" in the cash balance that doesn't come from a stock offering is a clear indicator of the settlement's size.

3. Strategic Silence (The "Citadel Factor")

There is a strategic reason why NWBO might keep the exact number quiet in the 10-Q:

Remaining Defendants: NWBO is still fighting Citadel Securities, Virtu, and Susquehanna. If they reveal that Canaccord settled for a "small" amount, it might embolden the remaining giants to fight harder.

If they reveal a "Large" amount: It signals to the other defendants that NWBO now has a massive "war chest" to fund the litigation for years, which could force the others to the settlement table sooner.

What I will be "Hunting" for in the Fine Print:

The "Subsequent Events" Section: Since the Canaccord dismissal was finalized in early May, it technically happened after the Q1 period ended. Management is required to disclose major events that occurred between March 31 and the filing date. This is where the mention of settlement proceeds will likely hide.

"Other Income" vs. "Financing": I will check if the cash increase came from the settlement (Other Income) or another stock offering (Financing). This is critical for your "non-dilutive" thesis.

Legal Spend: I’ll track the "Professional Fees" line. If legal spending is dropping, it suggests they are shifting from "active battle" to "data discovery," which preserves cash for the Sawston manufacturing scale-up.